Component
Simvastatin 20 mg daily
The lower of the two randomised dose arms.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
Myopathy occurred in 2 of 6,033 participants taking 20 mg simvastatin daily and in 53 of 6,031 taking 80 mg daily.
Experimental context and source evidence
- duration
- Mean follow-up 6.7 years
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- 12,064 men and women aged 18-80 with a history of myocardial infarction
- exposure
- 80 mg versus 20 mg simvastatin daily, randomised double-blind
- limitations
- Dose is the randomised variable, not measured plasma concentration; the trial's primary endpoint was major vascular events and myopathy was a safety outcome. The trial was funded by the drug's manufacturer.
- organism
- 12,064 men and women aged 18-80 with a history of myocardial infarction
- plain_language
- Myopathy occurred in 2 of 6,033 participants taking 20 mg simvastatin daily and in 53 of 6,031 taking 80 mg daily.
- primary_references
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. (2010). https://pubmed.ncbi.nlm.nih.gov/21067805/ DOI: 10.1016/S0140-6736(10)60310-8
- route
- Oral
- tissue
- Myopathy as an adverse outcome
Statin plasma exposure and muscle injury: dose randomisation and a drug interaction (2026-09-22) · lines 13–22
Original AI-assisted curation of three primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Two share a research group with the OATP1B1 collection and are recorded as one line of evidence with it. Study-specific doses, effect sizes and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft
## simvastatin-dose-raises-myopathy Myopathy occurred in 2 of 6,033 participants taking 20 mg simvastatin daily and in 53 of 6,031 taking 80 mg daily. Model/species: 12,064 men and women aged 18-80 with a history of myocardial infarction Tissue/system: Myopathy as an adverse outcome Exposure: 80 mg versus 20 mg simvastatin daily, randomised double-blind Route: Oral Duration: Mean follow-up 6.7 years Limits: Dose is the randomised variable, not measured plasma concentration; the trial's primary endpoint was major vascular events and myopathy was a safety outcome. The trial was funded by the drug's manufacturer. Primary reference: Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. (2010). https://pubmed.ncbi.nlm.nih.gov/21067805/ DOI: 10.1016/S0140-6736(10)60310-8 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.